IRIS
CORTI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.888
EU - Europa 5.135
NA - Nord America 3.927
SA - Sud America 1.562
Continente sconosciuto - Info sul continente non disponibili 144
AF - Africa 129
OC - Oceania 4
Totale 16.789
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.735
RU - Federazione Russa 3.019
SG - Singapore 2.154
CN - Cina 1.914
BR - Brasile 1.286
HK - Hong Kong 742
SE - Svezia 687
VN - Vietnam 522
IT - Italia 348
FR - Francia 270
RO - Romania 269
DE - Germania 181
BD - Bangladesh 170
AR - Argentina 107
GB - Regno Unito 94
IN - India 93
CA - Canada 81
FI - Finlandia 78
EC - Ecuador 59
MX - Messico 53
ID - Indonesia 52
IE - Irlanda 44
ZA - Sudafrica 43
AT - Austria 39
IQ - Iraq 33
JP - Giappone 33
CO - Colombia 31
PY - Paraguay 29
NL - Olanda 25
PL - Polonia 24
TR - Turchia 23
MA - Marocco 18
ES - Italia 16
JM - Giamaica 16
EG - Egitto 15
PK - Pakistan 15
UZ - Uzbekistan 15
MY - Malesia 14
SA - Arabia Saudita 14
VE - Venezuela 14
PE - Perù 13
CL - Cile 11
AE - Emirati Arabi Uniti 10
KE - Kenya 10
UA - Ucraina 10
UY - Uruguay 10
LT - Lituania 9
NP - Nepal 9
TN - Tunisia 9
AZ - Azerbaigian 8
IR - Iran 8
PH - Filippine 8
DO - Repubblica Dominicana 7
AL - Albania 6
CR - Costa Rica 6
NG - Nigeria 6
TT - Trinidad e Tobago 6
DZ - Algeria 5
GE - Georgia 5
JO - Giordania 5
KR - Corea 5
KZ - Kazakistan 5
SN - Senegal 5
ET - Etiopia 4
GT - Guatemala 4
HN - Honduras 4
PA - Panama 4
TH - Thailandia 4
AU - Australia 3
BB - Barbados 3
BE - Belgio 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GA - Gabon 3
HR - Croazia 3
KW - Kuwait 3
LB - Libano 3
SV - El Salvador 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CY - Cipro 2
DM - Dominica 2
IL - Israele 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CD - Congo 1
CG - Congo 1
CH - Svizzera 1
GD - Grenada 1
GH - Ghana 1
GR - Grecia 1
KG - Kirghizistan 1
Totale 16.637
Salva come PNG Salva come JPEG
Città #
Singapore 866
Hong Kong 733
Moscow 670
San Jose 532
Dallas 522
Ashburn 414
Shanghai 304
Hefei 287
Council Bluffs 284
Lawrence 266
Princeton 266
Lauterbourg 236
Ho Chi Minh City 185
Beijing 142
São Paulo 119
New York 118
Milan 105
Hanoi 102
Santa Clara 94
Los Angeles 81
Helsinki 59
Rio de Janeiro 46
Dublin 41
Nuremberg 41
The Dalles 35
Pune 34
Da Nang 30
Rome 29
Guangzhou 28
Orem 26
Boardman 24
Frankfurt am Main 24
Phoenix 24
Tokyo 24
Chicago 23
Hangzhou 23
Montreal 23
Quito 23
Haiphong 22
Curitiba 21
Denver 21
Brooklyn 20
London 20
Warsaw 20
Columbus 19
Johannesburg 19
Munich 19
Brasília 18
Buffalo 18
Campinas 18
Chennai 18
Mexico City 18
Atlanta 17
Dhaka 17
Vienna 17
Guarulhos 16
Hải Dương 16
Stockholm 16
Belo Horizonte 15
Salvador 14
Seattle 14
Toronto 14
Goiânia 13
Guayaquil 13
Houston 13
Manchester 13
Poplar 13
Shenzhen 13
Turku 13
Asunción 12
Baghdad 12
Jakarta 12
Manaus 12
Porto Alegre 12
Santo André 12
Tashkent 12
Thái Bình 12
Washington 12
Boston 11
Fortaleza 11
Naples 11
San Francisco 11
Xi'an 11
Biên Hòa 10
Cape Town 10
Cleveland 10
Kingston 10
Lima 9
Montevideo 9
Recife 9
Ribeirão Preto 9
Sorocaba 9
Thái Nguyên 9
Wuxi 9
Can Tho 8
Cesano Boscone 8
Charlotte 8
Miami 8
Pittsburgh 8
Riyadh 8
Totale 7.715
Salva come PNG Salva come JPEG
Nome #
A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer 391
Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion 192
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth 177
[Activation and role of the tumor necrosis factor-alpha in congestive heart failure]. FT Attivazione e ruolo del fattore di necrosi tumorale alfa nello scompenso cardiaco congestizio. 146
Hematopoietic stem-and progenitor-cell gene therapy for hurler syndrome 141
Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer 134
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome 132
An innovative platform approach for the development of ex-vivo gene therapies for the treatment of lysosomal storage diseases with skeletal involvement 126
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 121
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins 121
Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods 118
A pilot phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma 117
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 111
Altered Chromogranin A Circulating Levels in Meniere’s Disease 110
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging 108
Chromogranin A plasma levels predict mortality in COVID-19 107
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study 105
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods 102
Aminopeptidase N (CD13)-positive bone marrow-derived cells induce angiogenesis and tumor growth: A potential non-malignant immune cell target against cancer 102
A receptor-antibody sandwich assay for teicoplanin. 94
Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models 94
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 93
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 91
Chromogranin-A production and fragmentation in patients with Takayasu arteritis. 90
Contrast enhanced photoacoustic detection of fibrillar collagen in the near infrared region-I 89
Affinity enhancement of complementary peptide recognition 89
A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8 89
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 89
Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis 88
A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. 88
Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells 87
A new method for rapid and simple pregnancy detection using gold-labelled antibodies 85
A rapid method for monitoring DNA labelling reactions with haptens. 85
A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins 85
A new chromogranin A-dependent angiogenic switch activated by thrombin 82
Quantification of Chromogranin A and Its Fragments in Biological Fluids 77
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours 76
Agents regulating vascular permeability 75
TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens 74
Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study 71
Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity 71
Spatiotemporal regulation of tumor angiogenesis by circulating chromogranin a cleavage and neuropilin-1 engagement 71
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy 70
A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates 69
Tumor targeting with biotinylated tumor necrosis factor alpha: Structure-activity relationships and mechanism of action on avidin pretargeted tumor cells 68
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides 67
Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype 67
Tumor necrosis factor-α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the successful treatment of patients with infliximab 67
Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action 66
Won't you come on in? How to favor lymphocyte infiltration in tumors 66
Breaching the blood–brain tumor barrier for tumor therapy 66
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif 65
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) 65
T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors 65
Mode of interaction between tumor-necrosis-factor-alpha and a monoclonal-antibody expressing a recurrent idiotype 64
IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines 64
Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care 63
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells 63
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha 63
STRUCTURAL BASIS FOR THE INTERATION OF ISODGR WITH RGD-BINDING SITE OF αvβ3 INTEGRIN 63
Mechanism of suramin-induced deoligomerization of tumor-necrosis-factor-alpha 63
Chromogranin A is preferentially cleaved into pro-angiogenic peptides in the bone marrow of multiple myeloma patients 63
Anti-idiotype monoclonal antibody directed against anti-TNF antibodies 63
Autocrine saturation of pro-urokinase receptors on human A431cells 63
Identification of an epitope of tumor-necrosis-factor (TNF) receptor-type-1 (p55) recognized by a TNF-alpha-antagonist monoclonal-antibody 63
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms 63
Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability 62
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy 62
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells 62
Tumour necrosis factor: Strategies for improving the therapeutic index 62
Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment 62
Monoclonal antibodies against the TNF type-I receptor, process for their production and use thereofAnticorpi monoclonali anti-recettore di tipo 1 del TNF alfa, procedimento per la loro produzione e loro uso 62
Cytokine conjugates (IL-12 –peptide conjugates) 61
Ways to improve tumor uptake and penetration of drugs into solid tumors 61
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism 61
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation 61
NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells 61
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer 60
Conversation galante: How the immune and the neuroendocrine systems talk to each other 60
Liposome-Mediated Therapy of Neuroblastoma 60
Anti-urokinase monoclonal antibody, matrix bearing it, test method, biochemical test kits which use it. 60
Cromogranina A per uso come reagente in un metodo diagnostico o prognostico 60
Oligomeric Tumor-necrosis factor alpha slowly converts into inactive forms at bioactive levels 60
Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A 59
Chromogranin A and the Tumor Microenvironment 59
Oxidation-induced structural changes of ceruloplasmin foster NGR-motifs deamidation that promote integrin binding and signaling 59
Chromogranin A Regulates Tumor Self-Seeding and Dissemination 58
Tumor-necrosis-factor (TNF)-alpha quantification by ELISA and bioassay - effects of TNF-alpha-soluble TNF-receptor (p55) complex dissociation during assay incubations 58
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 58
Selective immunoassay for the detection of pro-urokinase and urokinase 58
Fusion of cytokines and targeting peptides 58
Receptor-antibody sandwich assay. 58
Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality 58
Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for αvβ3-Integrin Targeting 58
The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key? 57
PCR amplification of antibody variable regions using primers that anneal to constant regions 57
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas 57
Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. 57
Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage 57
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications, and alternative roads 57
Totale 8.173
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 0 70 0 7 7 5 2 2 1 17
2022/20231.296 604 245 115 3 2 138 42 67 64 5 5 6
2023/2024417 5 8 62 36 26 88 24 33 0 18 37 80
2024/20253.632 461 37 54 101 80 265 744 277 649 504 226 234
2025/202610.378 698 934 771 1.635 678 199 945 746 2.734 504 181 353
2026/2027869 318 551 0 0 0 0 0 0 0 0 0 0
Totale 16.789